Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, owing in part to the often late stage at which it is diagnosed. Biomarker development for HCC aims to improve ...
Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks ...
Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...
NEW YORK, April 17, 2026--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific ...
Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
BrainTale unveils partnerships with leading research centers in Europe and in the US to ultimately improve brain care through biomarkers development. By powering precision neurology, the company ...
We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...
BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...
Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...
Healthcare Asia Magazine on MSN
Biomarkers market set for 11% CAGR on early detection push
The market was valued at $26.48b in 2025. The global cancer biomarkers market is projected to grow at a compound annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results